Cytokinetics scored a Phase 3 win for aficamten (brand name Myqorzo) in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), meeting twin primary endpoints in the pivotal Acacia-HCM trial. The study showed statistically significant improvements versus placebo at week 36 in patient-reported outcomes and maximal exercise performance. The results extend Cytokinetics’ cardiomyopathy franchise beyond obstructive HCM, where aficamten was cleared by the FDA in December. With continued commercialization early in the launch cycle, a regulatory green light for nHCM could substantially widen the treatable population. For biotech planning, the catalyst is straightforward: nHCM endpoint success is the kind of clinical evidence that can accelerate payer conversations and companion labeling expansions if regulators agree with the Phase 3 data package.